Houston energy giant expands implementation of Canadian startup's tech

big, big energy

. Photo via Getty Images

CruxOCM, a startup with a significant Houston presence that specializes in robotic industrial process automation for energy companies, has secured even more business from energy giant Phillips 66.

The value of the deal wasn’t disclosed.

Houston-based Phillips 66 has agreed to expand it use of CruxOCM’s pipeBOT technology to cover even more pipelines. The pipeBOT technology is designed to improve the safety and efficiency of control room operations for pipelines and reduce control room costs.

CruxOCM and Phillips 66 launched a test of pipeBOT in 2020.

CruxOCM, based in Calgary, Canada, says pipeBOT is engineered to decrease manual controls through intelligent automation. With this technology in place, the fatigue of control room operators declines, because as many as 85 percent fewer manual commands must be entered, according to CruxOCM. Therefore, control room operators can focus on higher-level tasks.

“At CruxOCM, we empower control room operators with modern software that enables the autonomous control rooms of tomorrow, within the safety constraints of today. We look forward to continuing to strengthen our relationship with Phillips 66 for many years to come,” Adam Marsden, chief revenue officer at CruxOCM, says in a news release.

Founded in 2017, Crux OCM (Crux Operations Control Management) established its Houston presence last year. Also in 2021, the startup raised $6 million in venture capital in a “seed extension” funding round. Bullpen Capital led the round, with participation from Angular Ventures, Root Ventures, Golden Ventures, Cendana Capital, and Industry Ventures.

In 2019, Angular Ventures and Root Ventures co-led a $2.6 million funding round.

A Canadian software company with operations in Houston raised fresh funding. Photo via Getty Images

Energy software company with Houston presence snags $6M in funding

money moves

CruxOCM, a Canadian tech startup that is establishing a Houston outpost, has collected $6 million in venture capital.

Bullpen Capital led the "seed extension" funding round, with participation from Angular Ventures, Root Ventures, Golden Ventures, Cendana Capital, and Industry Ventures. In 2019, two years after CruxCOM was founded, Angular Ventures and Root Ventures co-led a $2.6 million funding round.

Calgary-based CruxOCM, says the new capital will go toward expanding its product lines, boosting the efficiency of its installation process, and growing its North American team. The company plans to extend its product reach to operators of gas plants, gas pipelines, and offshore facilities.

The startup makes software for control rooms operated by energy companies.

"Control rooms are the brains, heart, and soul of the energy sector, and they are in dire need of innovation. Our mission to give control room operators superpowers will ensure the efficiency and safety of an essential infrastructure we rely on daily," Vicki Knott, co-founder and CEO of CruxOCM, says in a September 14 news release.

Knott is a chemical engineer and former control room operator.

The company's robotic industrial process automation (RIPA) serves as the foundation for CruxOCM's gatherBOT and pipeBOT automation products. The introduction of two more products — powerOPT and draOPT — is underway. Houston-based Phillips 66 is piloting the powerOPT technology.

CruxOCM works with companies that have market capitalizations of $17 billion to $77 billion to improve control room efficiency and safety through automation.

"CruxOCM's RIPA is a game-changer in the industry, and we're thrilled to be a part of this next growth stage," says Eric Wiesen, managing partner of Bullpen Capital. "RIPA is crucial for bringing increased efficiency into existing heavy-industry control room infrastructure while maintaining safety. Even as we prioritize green energy initiatives globally, oil and gas will still be instrumental in the energy transition, so we must use technology to automate where we can while helping companies to augment metrics in order to hit ESG goals."

Knott recently told InnovationMap that CruxOCM has three full-time employees in Houston and is on track to add more workers in sales, product development, and engineering.

The CEO continues to hunt for office space in North Houston. "Depending on the comfort level of employees, it could be open in the next few months," a company spokeswoman says.

Today, CruxOCM employs 18 people, including the three workers in Houston, and aims to add six more employees by the end of 2021.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston researchers develop dissolvable implant for targeted cancer drug delivery

cancer research

Researchers at Houston Methodist have developed a biodegradable implant that can be used to safely and consistently deliver drug treatments to tumors and then dissolve without the need for further surgery.

The implant is only the size of a grain of rice, but its potential is staggering. The biodegradable nanofibrous drug-eluting seed (b-NDES) works as a reservoir parked inside a soft tumor, where it can slowly release immune-stimulating drugs over time. This overcomes a consistent problem with drugs such as immune checkpoint inhibitors. Normal systemic administration sees comparatively little of the drug making its way to the tumor, with most of it circulating throughout the body. The b-NDES is like deploying a small guerrilla fighting force embedded in enemy territory, doing maximum damage to the entrenched tumor.

"To improve cancer treatment, we're trying to start a fire inside the tumor itself," Corrine Chua, associate professor in the Center for BioNanoengineering at Houston Methodist Research Institute, said in a news release. "By activating immune cells directly within the tumor microenvironment, those cells can then travel throughout the body and seek out cancer wherever it exists. The b-NDES platform was developed to help keep therapeutic drugs concentrated inside tumors while minimizing exposure to healthy tissues.”

Chua co-led the study with Alessandro Grattoni, chair and director of the Center for BioNanoengineering at Houston Methodist Research Institute.

The study included support from the Nancy Owens Breast Cancer Foundation and the National Institutes of Health/National Cancer Institute.

Chau and Grattoni used preclinical models of triple-negative breast cancer, an aggressive form of cancer that is estrogen receptor-negative, progesterone receptor-negative and HER2-negative. Because of the receptor negativity, some popular treatments like tamoxifen and trastuzumab are ineffective. Chemotherapy has been shown to be the best course of action.

The b-NDES implant is deployed alongside radiation drugs. It keeps the drugs focused on the tumor, reducing the amount of harmful side effects typically seen when drugs are circulated more widely in the body. In 60 percent of the models, tumors were eliminated and did not cause side effects beyond the tumor site. Once the drugs have been deployed, the implant breaks down naturally.

While promising, more research will have to be done to expand use to other tumor types.

"Although the study focused on triple-negative breast cancer models, the approach could have broader applications for solid tumors," Grattoni added in the release. "It could potentially be used in cancers where there is a tumor lesion accessible for placement, including pancreatic or lung cancers."

New Houston platform Same Day Reels launches for on-demand content creation

In The Moment

If an event doesn't happen on Instagram, did it even really happen? In today's social media-driven age of branding and audience engagement, the answer increasingly is no.

Houston entrepreneur Karen De Amat is looking to fill the online content creation needs of companies with her new venture, Same Day Reels, which launched in early August. It will serve as a platform to connect companies and brands with talent that can help turn an event into a viral moment as it is happening.

"Events move quickly, and social media moves even faster,” said De Amat. “Same Day Reels was built to help brands capture the moment while it still matters. We are creating a more efficient way for businesses and creators to work together. Brands need content faster, and creators need more opportunities to turn their talent into real work. Same Day Reels brings those needs together.”

The company is focused on adding livestreams and concurrent short video content to "activations, launches, fundraisers, grand openings, conferences, hospitality experiences, and private celebrations." Such content can significantly increase the visibility of a product or brand according to digital marketing brands like Wyzowl, whose data found 63 percent of people in 2026 prefer to learn about new products via short video.

Packages offered by Same Day Reels will include filming, editing, and publishing content within hours of the targeted event.

De Amat says that her content creation platform will be a way to preserve the excitement of events and launches by enshrining them with immediate social media-driven memories.

“Event content is no longer just something you post after the fact,” De Amat said. “It is part of how people experience, remember and share the moment.”

Previously, De Amat is also the founder and CEO of Social Behavior, an influencer marketing company she launched from her home in 2014. It quickly garnered an array of clients and thrust De Amat into the spotlight, including numerous appearances on Fox 26's The Isiah Factor. Influencer Marketing Hub named her one of the top CEOs of influencer marketing companies in Houston in 2025.

---

This article originally appeared on CultureMap.com.

Bristol Myers Squibb to build $2.3B Houston pharma manufacturing campus

coming soon

New Jersey-based pharmaceutical giant Bristol Myers Squibb Co. has officially named Houston as the home of its new state-of-the-art manufacturing site.

The 60,000-square-foot facility represents a $2.3 billion investment, according to a news release. It is expected to create 500 skilled jobs and will be located in Houston's Generation Park.

BMS first announced that it was considering Houston among 16 other cities for the facility in May. The new hub will manufacture small molecule, biologic and antibody-drug conjugates and is part of a $40 billion commitment to invest in the United States over five years. Construction is slated to begin next year, with the facility coming online in 2030.

"We're building the domestic manufacturing capabilities needed to deliver the next generation of medicines and support future scientific breakthroughs. Houston and the state of Texas offer the talent, infrastructure, and partnership needed to help bring that vision to life," Christopher Boerner, CEO and board chair of BMS, said in the release.

The new facility will feature a modular, multi-modal design, which will allow the company to reconfigure and add to its manufacturing capabilities over time. BMS says it expects the facility to "(grow) in scale and capability well beyond its opening configuration."

"Our decision to build this state-of-the-art manufacturing campus in Houston, Texas, reflects our confidence in the region’s ability to support a world-class, digitally advanced supply operation,” Karin Shanahan, EVP and chief supply chain and operations officer of BMS, added in the release. “This facility is designed to deliver the speed, quality, and reliability that patients depend on, combining flexible, modular manufacturing with advanced digital capabilities to ensure consistent supply across multiple modalities. It strengthens our ability to operate with resilience and positions us to reliably deliver medicines to patients today while adapting future demands.”

Texas Gov. Greg Abbott shared that the state has granted BMS a $4.89 million Texas Enterprise Fund (TEF) grant for the project. TEF grants, administered by the Texas Economic Development & Tourism Office, support business relocation or expansion projects that create "new, good-paying jobs in the community and attract significant new capital investment to the state." The development is also a qualified project under the Texas Jobs, Energy, Technology, and Innovation (JETI) program.

“Texas is a global hub for life sciences, where today’s innovations shape the future of healthcare,” Abbott said in a news release. “This $2.3 billion investment by Bristol Myers Squibb in the dynamic biotech ecosystem in Houston is a testament to the depth of our skilled workforce and the pipeline of talent coming through our nation-leading technical colleges and research universities. With lower operating costs and easy access to markets across the U.S. and the world, Texas drives affordability for consumers.”

"Bristol Myers Squibb’s announcement is a tremendous win for Texas and the Houston region, further reinforcing our position as a premier destination for life sciences and advanced manufacturing,” added Greater Houston Partnership President and CEO Steve Kean.

Last fall, Eli Lilly and Co. selected Generation Park, a 4,300-acre, master-planned commercial district near Lake Houston, for its $6.5 billion manufacturing plant. More than 300 locations in the U.S. competed for the factory. Read more here.

View All Listings